Journal article 541 views 163 downloads
Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
Esteban Jódar,
Marie Michelsen,
William Polonsky,
Rosangela Réa,
Anna Sandberg,
Tina Vilsbøll,
Mark Warren,
Signe Harring,
Uwe Ziegler,
Steve Bain 
Diabetes, Obesity and Metabolism
Swansea University Author:
Steve Bain
-
PDF | Version of Record
Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).
Download (1.08MB)
DOI (Published version): 10.1111/dom.14039
Abstract
Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6)
| Published in: | Diabetes, Obesity and Metabolism |
|---|---|
| ISSN: | 1462-8902 1463-1326 |
| Published: |
Wiley
2020
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa54313 |
| Keywords: |
cardiovascular disease, GLP-1 analogue, hypoglycaemia, incretin therapy, type 2 diabetes,weight control |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |